QURE Live signals | Maximize Profits with Getagraph.com

BUY 102044 min ago

@ $5.35

Issued: 14 Feb 2024 @ 12:06

Return: -17.49%

Previous signal: Feb 13 - 11:21

Previous signal: Sell

Return: -4.81 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 09:50):

Stats
Today's Volume	30 335.00
Average Volume	960 212
Market Cap	210.97M
EPS	$0 ( 2024-02-26 )
Next earnings date	( $-1.310 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.680
ATR14	$0.0190 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Kapusta Matthew C	Buy	150 000	Ordinary Shares
2024-03-01	Kapusta Matthew C	Buy	259 500	Stock Option (Right to Buy)
2024-03-01	Klemt Christian	Buy	49 500	Ordinary Shares
2024-03-01	Klemt Christian	Buy	85 500	Stock Option (Right to Buy)
2024-03-01	Abi-saab Walid	Buy	49 500	Ordinary Shares

INSIDER POWER
73.79
Last 98 transactions
Buy: 2 008 230 \| Sell: 329 878

Volume Correlation

Long: 0.19 (neutral)

Short: 0.71 (moderate)

Signal:(31.041) Neutral

Uniqure NV Correlation

10 Most Positive Correlations
LWAC	0.93
SRAC	0.873
AMRB	0.864
NETE	0.839
ACER	0.823
MMAC	0.807
MRCC	0.806

10 Most Negative Correlations
SVAC	-0.87
TLGT	-0.844
RCM	-0.833
ASTS	-0.832
RMRM	-0.824
LUNG	-0.82
TEAM	-0.805
MTSL	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Uniqure NV Correlation - Currency/Commodity

-0.42
( neutral )

-0.52
( weak negative )

0.00
( neutral )

-0.43
( neutral )

0.78
( moderate )

-0.43
( neutral )

Uniqure NV Financials

Annual	2023
Revenue:	$15.84M
Gross Profit:	$2.22M (13.98 %)
EPS:	$-6.47

Q4	2023
Revenue:	$6.69M
Gross Profit:	$-2.15M (-32.08 %)
EPS:	$-1.530

Q3	2023
Revenue:	$1.41M
Gross Profit:	$401 000 (28.50 %)
EPS:	$-1.880

Q2	2023
Revenue:	$2.42M
Gross Profit:	$1.07M (44.18 %)
EPS:	$-1.440

Financial Reports:

No articles found.

Uniqure NV

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.